Talk:Edward Tobinick

From Wikipedia, the free encyclopedia

This is the talk page for discussing improvements to the Edward Tobinick article.
Please sign and date your posts by typing four tildes (~~~~). Put new text under old text. Click here to start a new topic. New to Wikipedia? Welcome! Ask questions, get answers. This is not a forum for general discussion about the article's subject.	Be polite Assume good faith No personal attacks Be welcoming	Article policies No original research Neutral point of view Verifiability

This article was nominated for deletion on 26 June 2006. The result of the discussion was keep.

This is the content of UCLA's press release on January 11, 2008, available at http://www.newsroom.ucla.edu/portal/ucla/ucla-headlines-jan-11-2008-43001.aspx, which is the UCLA Newsroom site, accessed on January 12, 2008: New Drug May Help Combat Alzheimer’s Research by Dr. Edward Tobinick, assistant clinical professor of medicine at the David Geffen School of Medicine at UCLA, on a new drug that may help reverse some of the early symptoms of Alzheimer’s disease was featured Thursday by FOX News, BBC News, Bloomberg, the Times Online (U.K.), the Daily Telegraph (U.K.) and Asian News International and Wednesday by United Press International. Tobinick was quoted in the Bloomberg article. The previous edit was erroneous.Tnfinfo (talk) 22:52, 13 January 2008 (UTC)TNFinfo.

THis articles current state is appallingly bad. Midgley 12:56, 5 July 2006 (UTC)

Regarding: "He is an Assistant Clinical Professor of Medicine at the David Geffen School of Medicine at UCLA and in full-time private practice." Although Tobinick's PR material claims that he is affiliated with UCLA, his name does not turn up during a search of the faculty roster at the David Geffen School of Medicine: http://dgsom.healthsciences.ucla.edu/research/institution/search-faculty/. -AED 08:08, 22 July 2006 (UTC)

AED has searched the wrong database. Dr. Tobinick is listed as a member of the UCLA Clinical Faculty in the UCLA Department of Medicine's Clinical Faculty database at: http://www.clinfac.med.ucla.edu//. -tnfinfo 13:37 EDT, 22 July 2006 (UTC)

Not my fault that the proper link was not originally provided. Per Wikipedia:Citing sources, whomever made the assertion should have cited it properly in the first place. -AED 18:12, 24 July 2006 (UTC)

Regarding: "For these novel treatment methods he has been issued multiple U.S. patents, including 6,015,557 (Tumor necrosis factor antagonists for the treatment of neurological disorders) [3]; 6,177,077 [4]; 6,419,934 [5]; and 6,982,089 [6]." This is poorly written and needs to be clarified. In context of the article, the antecedent of "these novel treatment methods" appears to be patents 6,982,089 and 6,419,934; therfore, the article reads as though he has been issued multiple U.S. patents because he was issued other patents. -AED 05:48, 24 July 2006 (UTC)

Please address this comment or the statement will be removed. -AED 18:12, 24 July 2006 (UTC)

"These novel treatment methods" refers to anti-TNF treatment for neurological disorders, including Alzheimer's Disease, and anti-TNF treatment of influenza, with or without the addition of oseltamivir, and all three patent references are therefore appropriate (this addresses the comments immediately above and below) -tnfinfo 18:30 EDT, 24 July 2006 (UTC)

Sorry, but it still doesn't make sense. If "these novel treatment methods" refers to patents X and Y, then the sentence read as such: "For patents X and Y he has been issued multiple U.S. patents, including patents A, B, C, and D." -AED 22:49, 24 July 2006 (UTC)

If one reads the patents carefully, it will be apparent that the claims overlap, and, therefore, the wording as used makes sense. For example, the 6,015,557 patent claims anti-TNF treatment for neurological disorders; the 6,177,077 patent specifically claims anti-TNF treatment of Alzheimer's Disease, and the 6,419,934 patent claims anti-TNF treatment of myasthenia gravis, both of which are subsets of the larger universe of neurological disorders which are amenable to treatment with biological anti-TNF molecules, such as etanercept, the specific concept which was originated by the patent holder. Thank you for pointing out the link, which has been corrected. -tnfinfo 19:30 EDT, 24 July 2006 (UTC)

AED's changes have again required rewording due to his apparent bias. For example his wording "his website claims that the patented methods are original concepts" is unnecessary and improperly demeaning, since claims which are patented are a priori original, since novelty (originality) is a necessary prerequisite to obtain a patent. . -tnfinfo 08:26 EDT, 24 July 2006 (UTC)

Cease with the personal attacks. If you think my edits are improper or changes are necessary, then make them. Perhaps you should read Wikipedia:Autobiography prior to leveling charges of bias. -AED 18:12, 24 July 2006 (UTC)

Regarding: "In addition, he originated the concept of the potential utility of etanercept, alone or in combination with oseltamivir for treatment of influenza (U.S. patent 6,419,934, filed September 5, 2000 [2]), including H5N1 influenza (avian flu)." The citation for this statement does not refer to oseltamivir or influenza. The proper link needs to be supplied. -AED 18:29, 24 July 2006 (UTC)

Thanks for correcting the link. First of all, United States Patent 6,419,934 mentions influenza but not specifically "H5N1" or "avian flu". I don't doubt that the patent covers this, but as written it suggests that he had the uncanny ability to foresee way back in 2000 that H5N1 would be a problem in 2003. His letter to the editor regarding SARS does mention avian influenza but again it was written after well after the outbreak. -AED 23:16, 24 July 2006 (UTC)